Journal of Cerebrovascular and Endovascular Neurosurgery

Korean Society of Cerebravascular Surgeons (대한뇌혈관외과학회)
권호 표지
DOI QR코드

DOI QR Code

Usefulness of Middle Meningeal Embolization to Prevent Recurrent Spontaneous Chronic Subdural Hemorrhage

  • Sirh, Sooji (Department of Neurosurgery, Soonchunhyang University Seoul Hospital) ;
  • Park, Hye Ran (Department of Neurosurgery, Soonchunhyang University Seoul Hospital) ;
  • Park, Sukh Que (Department of Neurosurgery, Soonchunhyang University Seoul Hospital)
  • Received : 2017.06.23
  • Accepted : 2018.03.05
  • Published : 2018.03.31
⟨ Previous Next ⟩

Abstract

Spontaneous chronic subdural hematoma (SDH) is a rare condition that could develop in association with hematologic disease. A 66-year-old male developed a chronic SDH as an initial manifestation of chronic myelomonocytic leukemia (CMML). He experienced recurrent chronic subdural hemorrhage and newly developed intracerebral hemorrhage. Considering the scheduled long-term chemotherapy, bilateral middle meningeal artery (MMA) embolization was performed to prevent recurrence of subdural hemorrhage. Although pancytopenia occurred during the 7 months' follow-up period, residual chronic subdural hemorrhage was absorbed without recurrence. To our best knowledge, this is the first report of CMML with spontaneous chronic SDH. MMA embolization is potentially a useful and safe treatment option in the challenging clinical situations with underlying pathologies.

Keywords

References

  1. Abdulhamid MM, Li YM, Hall WA. Spontaneous acute subdural hematoma as the initial manifestation of chronic myeloid leukemia. J Neurooncol. 2011 Feb;101(3):513-6. https://doi.org/10.1007/s11060-010-0278-6
  2. Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013 Jun;37(6):609-13. https://doi.org/10.1016/j.leukres.2013.01.004
  3. Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011 Oct 6;118(14):3824-31. https://doi.org/10.1182/blood-2011-05-352039
  4. Bromberg JE, Vandertop WP, Jansen GH. Recurrent subdural haematoma as the primary and sole manifestation of chronic lymphocytic leukaemia. Br J Neurosurg. 1998 Aug;12(4):373-6. https://doi.org/10.1080/02688699844934
  5. Cambier N, Wattel E, Menot M, Guerci A, Chomienne C, Fenaux P. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. Leukemia. 1996 Jul;10(7):1164-7.
  6. Comanescu A, Rosca E, Bota M, Ninulescu G. Chronic subdural hematoma in a patient with acute myeloid leukemia and dural metastatic infiltration. Rom J Morphol Embryol. 2008;49(2):259-62.
  7. Feldman E, Cortes J, DeAngelo D, Holyoake T, Simonsson B, O'Brien SG, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Sep;22(9):1707-11. https://doi.org/10.1038/leu.2008.156
  8. Ichimura S, Horiguchi T, Inoue S, Yoshida K. Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms. J Neurosci Rural Pract. 2012 Jan;3(1):98-9. https://doi.org/10.4103/0976-3147.91978
  9. Khaladkar SM, Thakkar DK, Jantre MN, Kulkarni VM, Singh A. Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: a rare case report with review of literature. Med J DY Patil Univ. 2015 May-June;8(3):411-3 https://doi.org/10.4103/0975-2870.157113
  10. Kim MS, Lee DH, Lee YR, Kim DK, Bae SH, Hwang JY, et al. A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate. Korean J Hematol. 2010 Mar;45(1):73-5. https://doi.org/10.5045/kjh.2010.45.1.73
  11. Laumer R. Implantation of a reservoir for refractory chronic subdural hematoma. Neurosurgery. 2002 Mar; 50(3):672.
  12. Lee KS. History of chronic subdural hematoma. Korean J Neurotrauma. 2015 Oct;11(2):27-34. https://doi.org/10.13004/kjnt.2015.11.2.27
  13. Mandai S, Sakurai M, Matsumoto Y. Middle meningeal artery embolization for refractory chronic subdural hematoma. Case report. J Neurosurg. 2000 Oct;93(4):686-8. https://doi.org/10.3171/jns.2000.93.4.0686
  14. McDermott M, Fleming RJ, Vanderlinden GR, Tucker WS. Spontaneous arterial subdural hematoma. Neurosurgery. 1984 Jan;14(1):13-8. https://doi.org/10.1227/00006123-198401000-00004
  15. Mino M, Nishimura S, Hori E, Kohama M, Yonezawa S, Midorikawa H, et al. Efficacy of middle meningeal artery embolization in the treatment of refractory chronic subdural hematoma. Surg Neurol Int. 2010 Dec 13;1:78. https://doi.org/10.4103/2152-7806.73801
  16. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004. https://doi.org/10.1056/NEJMoa022457
  17. Olfa CW, Imen R, Leila K, Hichem K, Adnane A, Mourad C, et al. Diagnosis of chronic myeloid leukemia from acute intracerebral hemorrhage: a case report. J Acute Dis. 2015 Aug;4(3):252-4. https://doi.org/10.1016/j.joad.2015.03.004
  18. Rao TV, Deshpande D. Malignant subdural effusion. Acta Neurochir. 1980 Mar;52(1-2):61-5. https://doi.org/10.1007/BF01400948
  19. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008 Jul 1;112(1): 45-52. https://doi.org/10.1182/blood-2008-01-134858
  20. Sato M, Saito T, Yamaguchi K, Sakuma H. A case of acute subdural hematoma due to dural metastasis from malignant pleural mesothelioma. No Shinkei Geka. 1994 Mar;22(3):247-51.
  21. Song K, Rifkind J, Al-Beirouti B, Yee K, McCrae J, Messner HA, et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma. 2004 Aug;45(8):1633-6. https://doi.org/10.1080/10428190310001615666
  22. Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013 Apr 11;121(15): 3005-15. https://doi.org/10.1182/blood-2012-08-452938
  23. Takahashi K, Muraoka K, Sugiura T, Maeda Y, Mandai S, Gohda Y, et al. Middle meningeal artery embolization for refractory chronic subdural hematoma: 3 case reports. No Shinkei Geka. 2002 May;30(5):535-9.
  24. Tanaka T, Fujimoto S, Saitoh K, Satoh S, Nagamatsu K, Midorikawa H. Superselective angiographic findings of ipsilateral middle meningeal artery of chronic subdural hematoma in adults. No Shinkei Geka. 1998 Apr;26(4): 339-47.
  25. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. https://doi.org/10.1182/blood-2009-03-209262
  26. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug;87(4):743-5. https://doi.org/10.1111/j.1365-2141.1994.tb06733.x

Cited by

  1. Embolization of the middle meningeal artery in patients with chronic subdural hematoma-a systematic review and meta-analysis vol.162, pp.4, 2018, https://doi.org/10.1007/s00701-020-04266-0
  2. Middle Meningeal Artery Embolization for the Treatment of Bilateral Chronic Subdural Hematoma vol.12, pp.None, 2021, https://doi.org/10.3389/fneur.2021.651362
  3. Utilizing dual energy CT to distinguish blood from contrast leakage following middle meningeal artery embolization for chronic subdural hematomas vol.13, pp.10, 2021, https://doi.org/10.1136/neurintsurg-2020-016953